Loading
Nanoparticles: Synthesis and Applications / CRISPR and Genetic Engineering · Journal article
Nanotechnology · August 28, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review of CRISPR-nanoparticle hybrids as a theoretical platform for targeting biofilm-associated antimicrobial resistance. The authors identify multiple mechanistic targets (quorum-sensing, resistance genes, biofilm structure) and delivery barriers but acknowledge that no clinical trials exist for this application and that matched quantitative comparisons between nanoparticle platforms remain limited in the literature. The platform remains at the conceptual and preclinical stage, with significant translational barriers including manufacturing, immunogenicity, off-target risk, regulatory ambiguity, and biosafety concerns.
Narrative review. Conceptual: biofilm-associated, multidrug-resistant bacterial infections; no human or animal study populations described..
No clinical trials currently exist for CRISPR-nanoparticle hybrids in biofilm antimicrobial resistance applications. Lipid-nanoparticle-mediated CRISPR-Cas9 delivery and gold-nanoparticle CRISPR hybrids have been explored for antimicrobial co-delivery, but precise quantitative comparisons between platforms remain limited. Target genes include quorum-sensing regulators (lasR, rhlR, luxS), resistance genes (mcr-1, mecA, blaNDM-1, blaCTX-M-15), and biofilm structural genes (icaA, icaD, bap, csgD).
No primary efficacy or safety data; review describes theoretical framework and barriers rather than experimental results. No in vivo biofilm models, animal studies, or clinical trial data presented to support the proposed mechanism or safety profile.
This review identifies CRISPR-nanoparticle hybrids as a potential future approach to recalcitrant biofilm infections but provides no evidence of clinical efficacy or safety. Clinicians should recognize this as an emerging research concept requiring substantial preclinical validation, regulatory clarification, and safety characterization before any consideration for clinical use.
This is a mechanistic review of an emerging platform concept with no clinical trial data, analyzing barriers and theoretical potential rather than testing efficacy in humans or animals.
As stated by the source record.
This review identifies CRISPR-nanoparticle hybrids as a potential future approach to recalcitrant biofilm infections but provides no evidence of clinical efficacy or safety. Clinicians should recognize this as an emerging research concept requiring substantial preclinical validation, regulatory clarification, and safety characterization before any consideration for clinical use.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Abstract Antimicrobial resistance represents a critical global health threat that outpaces the development of new antibiotics. Biofilms impose a multifaceted barrier, comprising an extracellular polymeric substance matrix of polysaccharides, proteins, and extracellular DNA, that limits antibiotic penetration and facilitates horizontal gene transfer of resistance determinants. This review adopts a biofilm-centered engineering framework to evaluate clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 nanoparticle hybrids as an emerging precision antimicrobial strategy, analyzing the sequential barriers of matrix penetration, bacterial envelope traversal, intracellular cargo release, and resistance-network reprogramming that determine therapeutic success. Lipid-nanoparticle-mediated CRISPR-Cas9 delivery and gold-nanoparticle CRISPR hybrids have been explored for antimicrobial co-delivery applications; precise, matched quantitative comparisons between nanoparticle platforms specific to biofilm CRISPR delivery remain limited in the primary literature. By precisely targeting quorum-sensing regulators ( lasR, rhlR, luxS ), resistance genes ( mcr-1, mecA, blaNDM-1, blaCTX-M-15 ), and biofilm structural genes ( icaA, icaD, bap, csgD ), this platform is designed to convert biofilm from an obstacle into a targetable interface. However, clinical translation faces major hurdles, including manufacturing complexity, immunogenicity, off-target risks, regulatory ambiguity between nanomedicine and gene therapy frameworks, and long-term biosafety concerns such as horizontal gene transfer. This review concludes that CRISPR-nanoparticle hybrids offer a transformative platform for precision antimicrobial intervention; however, no clinical trials currently exist for this specific application, and coordinated advances in nanoparticle engineering, safety characterization, and regulatory science are essential for clinical deployment against recalcitrant, multidrug-resistant biofilm infections.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.